MA45125A - Anticorps anti-alpha-synucléine et leurs utilisations - Google Patents

Anticorps anti-alpha-synucléine et leurs utilisations

Info

Publication number
MA45125A
MA45125A MA045125A MA45125A MA45125A MA 45125 A MA45125 A MA 45125A MA 045125 A MA045125 A MA 045125A MA 45125 A MA45125 A MA 45125A MA 45125 A MA45125 A MA 45125A
Authority
MA
Morocco
Prior art keywords
alpha
synuclein antibodies
synuclein
antibodies
Prior art date
Application number
MA045125A
Other languages
English (en)
Other versions
MA45125B1 (fr
Inventor
Lorraine Irving
Michael Perkinton
Darren Schofield
George Thom
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MA45125A publication Critical patent/MA45125A/fr
Publication of MA45125B1 publication Critical patent/MA45125B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
MA45125A 2016-06-02 2017-06-01 Anticorps anti-alpha-synucléine et leurs utilisations MA45125B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662344746P 2016-06-02 2016-06-02
PCT/EP2017/063406 WO2017207739A1 (fr) 2016-06-02 2017-06-01 Anticorps anti-alpha-synucléine et leurs utilisations

Publications (2)

Publication Number Publication Date
MA45125A true MA45125A (fr) 2021-06-02
MA45125B1 MA45125B1 (fr) 2021-11-30

Family

ID=59021492

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45125A MA45125B1 (fr) 2016-06-02 2017-06-01 Anticorps anti-alpha-synucléine et leurs utilisations

Country Status (37)

Country Link
US (5) US10160800B2 (fr)
EP (2) EP4000632A1 (fr)
JP (4) JP7078552B2 (fr)
KR (1) KR102499438B1 (fr)
CN (2) CN109475616B (fr)
AR (1) AR108663A1 (fr)
AU (2) AU2017272804B2 (fr)
BR (1) BR112018074978A2 (fr)
CA (1) CA3025987A1 (fr)
CL (1) CL2018003438A1 (fr)
CO (1) CO2018014010A2 (fr)
CY (1) CY1124896T1 (fr)
DK (1) DK3463435T3 (fr)
EA (2) EA202191380A1 (fr)
EC (1) ECSP18096095A (fr)
ES (1) ES2903402T3 (fr)
GE (2) GEP20217253B (fr)
HR (1) HRP20211935T1 (fr)
HU (1) HUE057214T2 (fr)
IL (1) IL263243A (fr)
LT (1) LT3463435T (fr)
MA (1) MA45125B1 (fr)
MD (1) MD3463435T2 (fr)
MX (1) MX393740B (fr)
MY (1) MY188183A (fr)
PE (2) PE20250392A1 (fr)
PH (1) PH12018502538A1 (fr)
PL (1) PL3463435T3 (fr)
PT (1) PT3463435T (fr)
RS (1) RS62682B1 (fr)
SG (1) SG11201810420YA (fr)
SI (1) SI3463435T1 (fr)
SM (1) SMT202200008T1 (fr)
TW (2) TW202309093A (fr)
UA (1) UA124733C2 (fr)
WO (1) WO2017207739A1 (fr)
ZA (1) ZA201808582B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
RU2019114679A (ru) 2016-11-15 2020-12-17 Х. Лундбекк А/С Средства, пути применения и способы лечения синуклеопатии
EP3555127B1 (fr) 2016-12-16 2024-12-18 H. Lundbeck A/S Agents, utilisations et procédés
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
BR112021006123A2 (pt) * 2018-10-19 2021-07-20 Janssen Vaccines & Prevention B.V. anticorpos anti-sinucleína
TWI734279B (zh) * 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
CA3133909A1 (fr) 2019-04-18 2020-10-22 Elpida TSIKA Nouvelles molecules pour la therapie et le diagnostic
CN110172098B (zh) * 2019-05-27 2023-03-10 长春工业大学 抗α-突触核蛋白的单克隆抗体及其应用
WO2021055881A1 (fr) 2019-09-20 2021-03-25 Denali Therapeutics Inc. Anticorps anti-alpha-synucléine et leurs procédés d'utilisation
KR102239512B1 (ko) * 2020-09-10 2021-04-12 서울대학교산학협력단 다중기능성 마이크로캡슐 조성물 및 그 제조방법
WO2022079297A1 (fr) 2020-10-16 2022-04-21 Ac Immune Sa Anticorps se liant à l'alpha-synucléine à usage thérapeutique et diagnostique
CN112920274A (zh) * 2021-03-17 2021-06-08 江苏贝格尔生物医药有限公司 一种检测alpha-synuclein蛋白的鼠单克隆抗体及其应用
CN113912716B (zh) * 2021-12-15 2022-03-01 北京凯祥弘康生物科技有限公司 针对α-突触核蛋白抗原的抗体及其应用
US20240279316A1 (en) 2022-12-29 2024-08-22 Astrazeneca Ab Compositions and methods for treating alpha-synucleinopathies

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2361704C (en) 2000-03-03 2006-08-02 Cambridge Antibody Tech Human antibodies against eotaxin and their use
CA2441903C (fr) 2000-05-26 2012-07-31 National Research Council Of Canada Anticorps cibles sur le cerveau a domaine unique, derives d'anticorps de lama
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
DK2361928T3 (en) 2003-05-19 2017-07-03 Prothena Biosciences Ltd Truncated fragments of alpha synuclein in Lewy body disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2005047860A2 (fr) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Anticorps a l'alpha-synucleine
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
EP1943341A4 (fr) 2005-09-27 2010-07-07 Ca Nat Research Council Epitopes de barriere hematoencephalique et leurs utilisations
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
PL2583978T3 (pl) 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
JP4934074B2 (ja) 2007-03-07 2012-05-16 株式会社アルファ スイッチ固定構造
ES2709048T3 (es) 2008-04-29 2019-04-15 Bioarctic Ab Anticuerpos y vacunas para su uso en métodos terapéuticos y diagnósticos para trastornos relacionados con alfasinucleína
HRP20150831T1 (hr) 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
JP4654348B1 (ja) 2010-02-23 2011-03-16 多摩川精機株式会社 検出装置用巻線の正弦波巻線方法
CN110655573B (zh) 2010-02-26 2023-07-18 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
PL2723379T3 (pl) 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
EP2771031B1 (fr) 2011-10-28 2018-04-18 Prothena Biosciences Limited Anticorps humanisés qui reconnaissent l'alpha-synucléine
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
LT3071597T (lt) * 2013-11-21 2020-10-12 F. Hoffmann-La Roche Ag Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
RS62003B2 (sr) 2014-11-10 2025-01-31 Medimmune Ltd Vezujući molekuli specifični za cd73 i njihove upotrebe

Also Published As

Publication number Publication date
SG11201810420YA (en) 2018-12-28
MY188183A (en) 2021-11-24
EA038358B1 (ru) 2021-08-13
KR20190013923A (ko) 2019-02-11
GEAP202114964A (en) 2021-01-25
US20250263477A1 (en) 2025-08-21
KR102499438B1 (ko) 2023-02-14
US20190276522A1 (en) 2019-09-12
BR112018074978A2 (pt) 2019-03-12
UA124733C2 (uk) 2021-11-10
AR108663A1 (es) 2018-09-12
EA201892548A1 (ru) 2019-06-28
LT3463435T (lt) 2021-12-27
TW202309093A (zh) 2023-03-01
TW201802119A (zh) 2018-01-16
CL2018003438A1 (es) 2019-03-22
MD3463435T2 (ro) 2022-03-31
MX393740B (es) 2025-03-24
EP3463435A1 (fr) 2019-04-10
GEP20217253B (en) 2021-05-13
CY1124896T1 (el) 2023-01-05
TWI765890B (zh) 2022-06-01
US20180002411A1 (en) 2018-01-04
AU2024200601A1 (en) 2024-04-18
US20210179698A1 (en) 2021-06-17
EA202191380A1 (ru) 2021-08-26
JP2022110117A (ja) 2022-07-28
PL3463435T3 (pl) 2022-02-14
WO2017207739A1 (fr) 2017-12-07
ECSP18096095A (es) 2019-01-31
ZA201808582B (en) 2021-08-25
US20230331830A1 (en) 2023-10-19
PH12018502538A1 (en) 2019-04-08
CN109475616A (zh) 2019-03-15
CN109475616B (zh) 2022-10-18
CA3025987A1 (fr) 2017-12-07
AU2017272804A1 (en) 2018-12-13
SI3463435T1 (sl) 2022-02-28
JP2024123247A (ja) 2024-09-10
US10889639B2 (en) 2021-01-12
MA45125B1 (fr) 2021-11-30
PE20190440A1 (es) 2019-03-27
HUE057214T2 (hu) 2022-04-28
ES2903402T3 (es) 2022-04-01
NZ748616A (en) 2025-08-29
SMT202200008T1 (it) 2022-03-21
DK3463435T3 (da) 2021-11-22
PT3463435T (pt) 2021-11-22
US10160800B2 (en) 2018-12-25
US11560424B2 (en) 2023-01-24
EP3463435B1 (fr) 2021-10-13
IL263243A (en) 2018-12-31
CN116120445A (zh) 2023-05-16
PE20250392A1 (es) 2025-02-11
CO2018014010A2 (es) 2019-01-18
JP2019527194A (ja) 2019-09-26
AU2017272804B2 (en) 2023-11-23
HRP20211935T1 (hr) 2022-03-18
JP7823118B2 (ja) 2026-03-03
EP4000632A1 (fr) 2022-05-25
MX2018014456A (es) 2019-08-12
RS62682B1 (sr) 2021-12-31
JP2026086794A (ja) 2026-05-26
JP7078552B2 (ja) 2022-05-31

Similar Documents

Publication Publication Date Title
FR24C1023I2 (fr) Anticorps thérapeutiques et leurs utilisations
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3504243A4 (fr) Anticorps anti-tim-3 et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3383916A4 (fr) Anticorps anti-cd73 et leurs utilisations
EP3426288A4 (fr) Anticorps anti-pacap et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3389702A4 (fr) Anticorps anti-lag-3 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
EP3759143A4 (fr) Anticorps anti-tigit et leurs utilisations
EP3661965A4 (fr) Anticorps anti-cd47 et leurs utilisations
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
MA49683A (fr) Anticorps anti-cd8 et leurs utilisations
MA45235A (fr) Anticorps anti-c5 et leurs utilisations
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
EP3328895A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
EP3283517A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3383904A4 (fr) Anticorps ctla-4 et leurs utilisations
EP3377102A4 (fr) Anticorps anti-pd-1 et leurs utilisations thérapeutiques
EP3645563A4 (fr) Anticorps anti-fam19a5 et leurs utilisations
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
EP3362482A4 (fr) Anticorps anti-pcsk9 et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations